Georgia SB 220 (2026) — "Putting Georgia’s Patients First Act"

Last verified: May 2026

What SB 220 Would Do

If signed by Gov. Brian Kemp by ~May 12, 2026, SB 220 would substantially expand and modernize Georgia’s medical-cannabis program. The bill is the most significant cannabis-policy expansion since HB 324 of 2019. Key changes:

1. Renaming — "Low THC Oil" → "Medical Cannabis"

SB 220 would replace "low THC oil" with "medical cannabis" throughout state law. The renaming is more than cosmetic: GMCC’s own annual reports have repeatedly noted that "low THC oil" sounds like a watered-down hemp product rather than therapeutic medical cannabis — one of the program’s structural barriers to patient adoption.

2. Removing the 5% THC Cap

The 5% THC potency cap (with CBD≥THC requirement) under O.C.G.A. § 16-12-191 is the most-restrictive THC cap of any U.S. state medical-cannabis program. It excludes most products patients see in press coverage of medical cannabis. SB 220 would replace the percentage cap with a milligram-based possession ceiling: 12,000 mg total THC at any one time, with individual product packages capped at 1,200 mg.

3. Authorizing Vaporization

Vaporization (not smoking) would be authorized for patients 21 and older, in private settings, no later than January 1, 2027. The 21+ floor is unusual — the existing program is open to qualifying patients of any age — but the vaporization authorization is restricted to adult patients.

4. Adding Three Qualifying Conditions

The list expands to add:

• Lupus.
• Severe arthritis.
• Severe insomnia.

5. Removing the "Severe or End-Stage" Qualifier

The "severe or end-stage" qualifier on cancer, MS, Parkinson’s, Alzheimer’s, and other named conditions would be removed — substantially expanding patient eligibility within the existing diagnostic categories. A patient with a documented diagnosis but moderate disease progression would qualify; under current law, only patients with severe or end-stage disease qualify.

6. Tightening Certifying-Physician Oversight

Certifying physicians would be required to maintain a "principal place of practice" in Georgia — closing what Rep. Mark Newton (R-Augusta) called a "loophole" used by an out-of-state telemedicine physician who had certified roughly 4,000 Georgia patients. The change would tighten the bona-fide-relationship standard.

What SB 220 Would NOT Do

Even if signed, SB 220 would still leave Georgia’s medical-cannabis program with significant restrictions absent in most other state programs:

• No smokable flower. Cannabis flower remains banned regardless of SB 220.
• No conventional edibles. Cookies, brownies, candies (other than authorized lozenges) remain banned.
• No home cultivation. Home grow remains illegal under all circumstances.
• No recreational cannabis. Adult-use legalization is not in SB 220.
• No reciprocity beyond first 30 days of GA residency. Out-of-state cardholders still cannot access the Georgia program after that window.

If SB 220 takes effect, Georgia will move from the most restrictive U.S. medical cannabis program to one closer in design to Tennessee’s hemp regime than to Florida’s full-spectrum program.

The Politics

SB 220 is the product of multiple legislative cycles of pro-medical-expansion advocacy:

• Sen. Matt Brass (R-Newnan) — primary sponsor with 20 bipartisan co-sponsors. Brass replaced the more cautious 2024 version with a more ambitious framework after the 2024 Blue-Ribbon Study Committee on Medical Cannabis and Hemp Policies recommendations.
• Rep. Mark Newton MD (R-Augusta) — physician-legislator who chaired the 2024 House Blue-Ribbon Study Committee and carried SB 220 in the House.
• Rep. Devan Seabaugh (R-Cobb County) — aligned with Cobb-area medical-cannabis families; supported the 2023 dispensary launches publicly.
• Sen. Bill Cowsert (R-Athens) and Sen. Kay Kirkpatrick MD (R-Marietta) — longtime pro-medical-expansion voices in the Senate.

Gov. Kemp has signaled openness to SB 220’s milligram-based framework, in contrast to his caution on broader recreational reform. Kemp cannot run for re-election in 2026 due to term limits.

What to Watch on May 12, 2026

• Sign: SB 220 takes effect on the statutory effective date; vaporization authorization triggers no later than January 1, 2027.
• Veto: The General Assembly could attempt an override (requires 2/3 vote in both chambers); historically rare in Georgia.
• Allow to become law without signature: Same effect as a sign — the bill becomes law.

The same May 12, 2026 deadline applies to SB 33 (synthetic hemp ban) and SB 254 (THC beverage ban) on the hemp side. See pending hemp bills page.

Why This Decision Is Pivotal

Georgia’s adoption rate is the lowest of any U.S. medical-cannabis program (~0.3%). The structural reasons — 5% THC cap, no smokable flower or edibles, the "low THC oil" naming — are all addressed by SB 220. If signed, registry adoption is expected to rise materially over 2026–2027 as practitioners certify the broader patient population now eligible.

If vetoed or stalled, Georgia’s program continues at current scale (~34,500 patients) and the de facto cannabis market remains the hemp-derived intoxicant sector regulated by SB 494 of 2024.